SenesTech, Inc., a company specializing in fertility control products for pest management, has announced a significant financial event involving its common stock. The company has filed a prospectus related to the resale of 1,036,279 shares of common stock by identified selling stockholders. These shares represent those issuable upon the exercise of outstanding warrants, including Common Stock Warrants and Placement Agent Warrants, with exercise prices of $4.35 and $5.75 per share, respectively. The selling stockholders may sell the shares through various methods, including ordinary brokerage transactions, block trades, or private negotiations. SenesTech will not receive proceeds from the resale of shares, except for cash proceeds from the exercise of warrants. The company's common stock is listed on The Nasdaq Capital Market under the...Show More

SenesTech, Inc., a company specializing in fertility control products for pest management, has announced a significant financial event involving its common stock. The company has filed a prospectus related to the resale of 1,036,279 shares of common stock by identified selling stockholders. These shares represent those issuable upon the exercise of outstanding warrants, including Common Stock Warrants and Placement Agent Warrants, with exercise prices of $4.35 and $5.75 per share, respectively. The selling stockholders may sell the shares through various methods, including ordinary brokerage transactions, block trades, or private negotiations. SenesTech will not receive proceeds from the resale of shares, except for cash proceeds from the exercise of warrants. The company's common stock is listed on The Nasdaq Capital Market under the symbol 'SNES.' As of September 20, 2024, the last reported sale price of SenesTech's common stock was $2.50 per share. The prospectus also highlights the risks associated with investing in SenesTech's securities, urging potential investors to read the 'Risk Factors' section. The company has experienced operating losses since inception and anticipates continued significant expenses and operating losses in the foreseeable future. The prospectus is dated October 4, 2024.